Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

OCULAR THERAPEUTIX, INC.

(OCUL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société OCULAR THERAPEUTIX, INC.
01/19Ocular Therapeutix, Inc. - AFFAMED THERAPEUTICS, LICENSEE OF DEXTENZA IN CERTAIN ASIAN ..
AQ
01/18AffaMed Therapeutics, licensee of DEXTENZA® in Certain Asian Markets, Doses Their First..
BU
01/05Ocular therapeutix to present at the h.c. wainwright bioconnect 2022 virtual conference
AQ
01/04Ocular Therapeutix™ to Present at the H.C. Wainwright BioConnect 2022 Virtual Con..
BU
2021Ocular therapeutix announces topline results for phase 2 clinical trial of otx-ded for ..
AQ
2021Ocular Therapeutix™ Announces Topline Results for Phase 2 Clinical Trial of OTX-D..
BU
2021Patent Owner Loses Everything At PTAB
AQ
2021Ocular therapeutix to participate at two upcoming investor conferences
AQ
2021Ocular Therapeutix™ to Participate at Two Upcoming Investor Conferences
BU
2021Ocular Therapeutix™ Announces Success in Patent Appeal Brought by Mati Therapeuti..
BU
2021OCULAR THERAPEUTIX : Q3 Earnings Snapshot
AQ
2021Ocular Therapeutix™ Reports Third Quarter 2021 Financial Results and Business Upd..
PU
2021OCULAR THERAPEUTIX, INC Management's Discussion and Analysis of Financial Condition an..
AQ
2021Ocular Therapeutix™ Reports Third Quarter 2021 Financial Results and Business Upd..
BU
2021Ocular therapeutix announces update from the centers for medicare and medicaid services..
AQ
2021Ocular Therapeutix™ Announces Update from the Centers for Medicare and Medicaid S..
BU
2021Ocular Therapeutix™ to Present Data at the American Academy of Optometry Annual M..
BU
2021Ocular Therapeutix™ To Report Third Quarter 2021 Financial Results
BU
2021Ocular therapeutix to present data at the american academy of ophthalmology (aao) 2021 ..
AQ
2021Ocular Therapeutix™ to Present Data at the American Academy of Ophthalmology (AAO..
BU
2021OCULAR THERAPEUTIX : Announces topline results for phase 2 clinical trial of otx-csi for t..
AQ
2021OCULAR THERAPEUTIX : trade; Announces Topline Results for Phase 2 Clinical Trial of OTX-CS..
BU
2021OCULAR THERAPEUTIX : Announces FDA Approval of Supplemental New Drug Application (sNDA) fo..
AQ
2021OCULAR THERAPEUTIX : trade; Announces FDA Approval of Supplemental New Drug Application (s..
BU
2021OCULAR THERAPEUTIX : Announces appointment of karen-leigh edwards as senior vice president..
AQ
2021OCULAR THERAPEUTIX : trade; Announces Appointment of Karen-Leigh Edwards as Senior Vice Pr..
BU
2021Ocular therapeutix appoints merilee raines to its board of directors
AQ
2021OCULAR THERAPEUTIX, INC : Change in Directors or Principal Officers (form 8-K)
AQ
2021OCULAR THERAPEUTIX : trade; Appoints Merilee Raines to Its Board of Directors
BU
2021OCULAR THERAPEUTIX : Updates monthly in-market unit sales of dextenza billable inserts
AQ
2021OCULAR THERAPEUTIX : trade; Updates Monthly In-Market Unit Sales of DEXTENZA® Billable Ins..
BU
2021OCULAR THERAPEUTIX : trade; to Present at the H.C. Wainwright 23rd Annual Global Investmen..
BU
2021OCULAR THERAPEUTIX : To present at the h.c. wainwright ophthalmology virtual conference
AQ
2021OCULAR THERAPEUTIX : trade; to Present at the H.C. Wainwright Ophthalmology Virtual Confer..
BU
2021OCULAR THERAPEUTIX, INC : Entry into a Material Definitive Agreement, Other Events, Financ..
AQ
2021OCULAR THERAPEUTIX : Q2 Earnings Snapshot
AQ
2021OCULAR THERAPEUTIX : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
2021OCULAR THERAPEUTIX : trade; Reports Second Quarter 2021 Financial Results and Business Upd..
BU
2021OCULAR THERAPEUTIX : trade; Announces Termination of the Collaboration with Regeneron to D..
BU
2021OCULAR THERAPEUTIX : Announces first patient dosed in u.s.-based phase 1 clinical trial of..
AQ
2021OCULAR THERAPEUTIX : To report second quarter 2021 financial results
AQ
2021OCULAR THERAPEUTIX : trade; Announces First Patient Dosed in U.S.-based Phase 1 Clinical T..
BU
2021OCULAR THERAPEUTIX : trade; To Report Second Quarter 2021 Financial Results
BU
2021OCULAR THERAPEUTIX : Thinking about buying stock in Acorda Therapeutics, Ocular Therapeuti..
PR
2021OCULAR THERAPEUTIX : trade; To Present Clinical Data at the 2021 American Society of Catar..
BU
2021OCULAR THERAPEUTIX : Announces second quarter 2021 preliminary net product revenue of $11...
AQ
2021OCULAR THERAPEUTIX : Second Quarter 2021 Net Product Revenue Up Approximately 60% and In-M..
PU
2021OCULAR THERAPEUTIX : trade; Announces Second Quarter 2021 Preliminary Net Product Revenue ..
BU
2021OCULAR THERAPEUTIX : trade; and Mosaic Biosciences Enter into Strategic Discovery Collabor..
BU
2021OCULAR THERAPEUTIX : RESTATED CERTIFICATE OF INCORPORATION (Form 8-K)
PU
2021OCULAR THERAPEUTIX, INC : Submission of Matters to a Vote of Security Holders, Financial S..
AQ
2021OCULAR THERAPEUTIX : FOURTH AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (Form 8-K)
PU
2021OCULAR THERAPEUTIX, INC : Entry into a Material Definitive Agreement, Financial Statements..
AQ
2021OCULAR THERAPEUTIX : To participate at three upcoming investor conferences
AQ
2021OCULAR THERAPEUTIX : trade; to Participate at Three Upcoming Investor Conferences
BU
2021OCULAR THERAPEUTIX : DEXTENZA® Achieved Quarterly Record of 16,634 Billable Units Sold to ..
PU
2021OCULAR THERAPEUTIX : Reports first quarter 2021 financial results and business update
AQ
2021OCULAR THERAPEUTIX : Q1 Earnings Snapshot
AQ
2021OCULAR THERAPEUTIX : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
2021OCULAR THERAPEUTIX : trade; Reports First Quarter 2021 Financial Results and Business Upda..
BU
2021OCULAR THERAPEUTIX : Fulfills post-marketing approval requirements for resure sealant
AQ
2021OCULAR THERAPEUTIX : trade; Fulfills Post-Marketing Approval Requirements for ReSure® Seal..
BU
2021OCULAR THERAPEUTIX : To Present Pre-Clinical and Clinical Data at the 2021 Association for..
AQ
2021OCULAR THERAPEUTIX : To Report First Quarter 2021 Financial Results
AQ
2021OCULAR THERAPEUTIX : CORRECTING and REPLACING Ocular Therapeutix™ To Present Pre-Cli..
BU
2021OCULAR THERAPEUTIX : Update on DEXTENZA Unit Sales
PU
2021OCULAR THERAPEUTIX, INC : Results of Operations and Financial Condition (form 8-K)
AQ
2021OCULAR THERAPEUTIX : trade; To Report First Quarter 2021 Financial Results
BU
2021OCULAR THERAPEUTIX, INC : Change in Directors or Principal Officers (form 8-K)
AQ
2021OCULAR THERAPEUTIX : Reports fourth quarter and year end 2020 financial results and busine..
AQ
2021OCULAR THERAPEUTIX : Q4 Earnings Snapshot
AQ
2021OCULAR THERAPEUTIX : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
2021OCULAR THERAPEUTIX : trade; Reports Fourth Quarter and Year End 2020 Financial Results and..
BU
2021OCULAR THERAPEUTIX : trade; Announces FDA Acceptance of Supplemental New Drug Application ..
BU
2021OCULAR THERAPEUTIX : Announces First Patient Dosed in Phase 2 Clinical Trial of OTX-DED fo..
AQ
1  2  3  4  5  6Next
Upcoming event on OCULAR THERAPEUTIX, INC.